MOTIVATE 1 and 2 are randomized, double-blind, placebo (PBO)-controlled Phase III studies assessing the efficacy and safety of maraviroc (MVC) in TE patients with R5 HIV-1. In both studies, MVC (QD/BID) + optimized background therapy (OBT) demonstrated significantly greater virological and immunological efficacy and a similar safety profile compared with PBO+OBT at weeks 24 and 48 [1].
Purpose of the study MOTIVATE 1 and 2 are randomized, double-blind, placebo (PBO)-controlled Phase III studies assessing the efficacy and safety of maraviroc (MVC) in TE patients with R5 HIV-1. In both studies, MVC (QD/BID) + optimized background therapy (OBT) demonstrated significantly greater virological and immunological efficacy and a similar safety profile compared with PBO+OBT at weeks 24 and 48 [1] .
Methods
1,076 patients with triple drug-class experience and/or triple-class resistance, R5 virus (Trofile™), and HIV-1 RNA ≥5,000 copies/mL were randomized 1:2:2 to PBO, MVC QD or BID. All patients received OBT (3-6 antiretrovirals +/-low-dose ritonavir; darunavir/r not permitted due lack of PK data). The study was unblinded after week 48 (primary end-point). Patients in both MVC arms who had not experienced treatment failure through week 48 were rolled over to open-label MVC BID, but are referred to below by their baseline (BL) randomization assignment. The PBO arm contains patients who were virologically suppressed at week 48 and remained on OBT through week 96. After week 48, substitutions in OBT were allowed in all arms.
Summary of results
More patients in the MVC arms maintained HIV-1 suppression (to <400 and <50 copies/mL) through week 96 than those in the PBO arm. Fewer patients in the MVC arms experienced virologic failure between week 48 and 96 compared with the PBO arm. Incidence of SAEs, Category C events and malignancies were similar among treatment arms even when unadjusted for exposure, which was significantly greater in each of the MVC arms compared with the PBO arm. See table in Figure 1 .
Conclusion
MVC+OBT resulted in durable viral suppression through week 96 in these TE patients with R5 HIV-1. Pooled analyses revealed no new or unique safety signals between 48 and 96 weeks. Serious adverse events, Category C events and malignancies occurred with similar frequency among treatment groups. 
